

# Kim Lawson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5009031/publications.pdf>

Version: 2024-02-01

34  
papers

629  
citations

567281

15  
h-index

642732

23  
g-index

34  
all docs

34  
docs citations

34  
times ranked

696  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Effects of Natural H <sub>2</sub> S-Donors in Hypertension Management. <i>Biomolecules</i> , 2022, 12, 581.	4.0	16
2	Comorbid Conditions, Mental Health and Cognitive Functions in Adults with Fibromyalgia. <i>Western Journal of Nursing Research</i> , 2021, 43, 115-122.	1.4	3
3	Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options. , 2020, 4, .		10
4	Patients' perspective of the effectiveness and acceptability of pharmacological and non-pharmacological treatments of fibromyalgia. <i>Scandinavian Journal of Pain</i> , 2019, 19, 167-181.	1.3	20
5	Pharmacology and clinical applications of flupirtine: Current and future options. <i>World Journal of Pharmacology</i> , 2019, 8, 1-13.	2.3	9
6	Is there a role for melatonin in fibromyalgia?. <i>AIMS Molecular Science</i> , 2019, 6, 73-86.	0.5	1
7	What causes fibromyalgia? An online survey of patient perspectives. <i>Health Psychology Open</i> , 2018, 5, 205510291880268.	1.4	20
8	Flupirtine Is an Effective Analgesic. <i>Anesthesia and Analgesia</i> , 2018, 127, e24-e25.	2.2	2
9	Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis. <i>World Journal of Pharmacology</i> , 2018, 7, 1-9.	2.3	10
10	A qualitative exploration of the experiences of living with and being treated for fibromyalgia. <i>Health Psychology Open</i> , 2017, 4, 205510291772433.	1.4	41
11	A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia. <i>Biomedicines</i> , 2017, 5, 24.	3.2	34
12	Emerging pharmacological strategies for the treatment of fibromyalgia. <i>World Journal of Pharmacology</i> , 2017, 6, 1.	2.3	18
13	Potential drug therapies for the treatment of fibromyalgia. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1071-1081.	4.1	19
14	Clinical Trials for Patients with Fibromyalgia Syndrome. <i>Clinical &amp; Experimental Pharmacology</i> , 2014, 04, .	0.3	0
15	Innovative Approaches for the Complexity of Fibromyalgia. <i>Clinical &amp; Experimental Pharmacology</i> , 2013, 04, .	0.3	1
16	The role of calcium-positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin-induced diabetic rats. <i>BJU International</i> , 2011, 107, 1480-1487.	2.5	35
17	Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: Effect of potassium channel modulators. <i>European Journal of Pharmacology</i> , 2011, 660, 431-437.	3.5	12
18	Pregabalin and Fibromyalgia Syndrome: A Treatment Option. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1094.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Pharmacological treatments of fibromyalgia: Do complex conditions need complex therapies?. Drug Discovery Today, 2008, 13, 333-340.	6.4	18
20	Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatric Disease and Treatment, 2008, 4, 1059.	2.2	32
21	Are complex therapies required as pharmacological treatments of fibromyalgia?. Future Rheumatology, 2007, 2, 599-605.	0.2	3
22	Potassium Channels as Targets for the Management of Pain. Central Nervous System Agents in Medicinal Chemistry, 2006, 6, 119-128.	1.1	11
23	Increasing awareness and recognition of fibromyalgia. International Journal of Therapy and Rehabilitation, 2003, 10, 244-244.	0.1	0
24	Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?. Expert Opinion on Investigational Drugs, 2002, 11, 1437-1445.	4.1	30
25	Peripheral channelopathies as targets for potassium channel openers. Expert Opinion on Investigational Drugs, 2001, 10, 1345-1359.	4.1	19
26	The Pharmacotherapy of Common Functional Syndromes. Physiotherapy, 2001, 87, 108.	0.4	0
27	Potassium channel openers as potential therapeutic weapons in ion channel disease. Kidney International, 2000, 57, 838-845.	5.2	104
28	Is there a role for potassium channel openers in neuronal ion channel disorders?. Expert Opinion on Investigational Drugs, 2000, 9, 2269-2280.	4.1	37
29	Therapeutic Applications of Anti-depressant Drugs in Fibromyalgia Syndrome. Physiotherapy, 1999, 85, 197-200.	0.4	1
30	Tizanidine. Physiotherapy, 1998, 84, 418-420.	0.4	1
31	Is there a Therapeutic Future for $\sim$ Potassium Channel Openers $\hat{e}$ ™?. Clinical Science, 1996, 91, 651-663.	4.3	21
32	Potassium channel activation: A potential therapeutic approach?. , 1996, 70, 39-63.		80
33	Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. British Journal of Pharmacology, 1992, 107, 58-65.	5.4	14
34	Contractile responses to calcium chloride in rat aortic rings bathed in $K^{+}$ -free solution are resistant to organic calcium antagonists. British Journal of Pharmacology, 1989, 96, 17-22.	5.4	7